Form4insider filings, from the source

SEC Form 4 · accession 0001193125-26-388142

Korsana Biosciences, Inc. · KRSA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Peter Evan Harwin
Director · 10% Owner
Fairmount Funds Management LLC
Director · 10% Owner
Tomas Kiselak
Director · 10% Owner
Period of report
Sep 9, 2026
Accepted (ET)
Sep 10, 2026 · 5:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001755237

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2,F1$26.20Sep 9, 2026A48,445A—Sep 9, 2036Common Stock48,44548,445I

Explanation of responses

Remarks

Fairmount, Fund II and Co-Invest may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a manager of Fairmount.